您好,欢迎您

【2023 ESMO】消化肿瘤领域LBA精华内容公布:渠清如许,活水源来

2023年09月30日
整理:肿瘤资讯
来源:肿瘤资讯

欧洲中部夏令时间2023年9月28日,欧洲内科肿瘤学会(ESMO)公布了即将召开的2023年ESMO大会上最为重磅的摘要LBAs(Late- Breaking Abstracts)题目及信息,覆盖Presidential Symposium(主席大会)、Proffered Paper Session(优选论文会议)、Mini Oral Session(简短口头摘要会议)所有口头摘要公布的会议。


据【肿瘤资讯】统计,在消化肿瘤领域,LBAs共计17项,其中,中国研究为3项。【肿瘤资讯】特将摘要信息整理如下,与您同鉴!

中国之声,弦歌不辍

上消化道领域

简短口头报告专场

摘要号:LBA78

题目:Overall Survival of Perioperative or Postoperative Adjuvant Oxaliplatin with S-1 versus Adjuvant Oxaliplatin with Capecitabine in Locally Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma Undergoing D2 Gastrectomy: An Updated Analysis of RESOLVE Trial

D2胃切除术治疗的局部进展期胃癌或胃食管结合部腺癌接受围手术期或术后辅助奥沙利铂联合S-1方案vs.辅助奥沙利铂加卡培他滨方案的总生存率比较:RESOLVE试验的更新分析

讲者:北京大学肿瘤医院 张小田教授

摘要号:LBA79 

题目:GEMSTONE-303: prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase 3 study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

GEMSTONE-303: 舒格利单抗联合化疗vs.安慰剂联合化疗治疗初治晚期胃癌或胃食管结合部(G/GEJ)腺癌的3期研究:预设无进展生存期(PFS)和总生存期(OS)最终分析 

讲者:北京大学肿瘤医院 张小田教授

摘要号:LBA80

题目:Tislelizumab (TIS) Plus Chemotherapy (Chemo) vs Placebo (PBO) Plus Chemo as First-Line (1L) Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GC/GEJC): Final Analysis Results of the RATIONALE-305 Study

替雷利珠单抗(TIS)联合化疗(Chemo)vs.安慰剂(PBO)联合化疗作为晚期胃癌或胃食管结合部腺癌(GC/GEJC)的一线(1L)治疗:RATIONALE-305研究的最终分析结果

讲者:中山大学肿瘤防治中心 徐瑞华教授

下消化道领域

优选论文专场

摘要号:LBA25

题目:Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: a randomized phase III trial (UNION)

局部晚期直肠癌新辅助短程放疗后卡瑞利珠单抗+化疗vs.长程放化疗后化疗的比较:一项随机III期试验(UNION)

讲者:华中科技大学同济医学院附属协和医院 林振宇教授

摘要号:LBA26

题目:Neoadjuvant Chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Tria

CAPOX新辅助化疗vs.放化疗治疗未累及直肠系膜筋膜的局部进展期直肠癌(CONVERT):一项III期试验的最终结果

讲者:中山大学肿瘤防治中心 丁培荣教授

国际风采,大海之阔

上消化道领域

优选论文专场

摘要号:LBA74

题目:Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The Phase 3 KEYNOTE-585 study

帕博利珠单抗联合化疗vs.化疗作为局部进展期胃癌和胃食管结合部癌新辅助和辅助治疗的比较:KEYNOTE-585 3期研究

讲者:日本国立癌症中心东医院 Kohei Shitara
 
摘要号:LBA73 

题目:Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): interim results of the global, Phase 3 MATTERHORN study

度伐利尤单抗联合5-氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛(FLOT)治疗可切除胃癌和胃食管结合部癌(GC/GEJC)的病理完全缓解(pCR):全球3期MATTERHORN研究的中期结果

讲者:未公布

摘要号:LBA75 

题目:Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): a phase-III stepped-wedge cluster randomised trial

食管癌新辅助放化疗后手术vs.主动监测的比较(SANO-试验):一项III期阶梯楔形集群随机试验

讲者:荷兰鹿特丹伊拉斯谟大学Berend J. Van der Wilk

摘要号:LBA83 

题目:Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial

FOLFIRINOX新辅助化疗vs.以吉西他滨为基础的新辅助放化疗治疗临界可切除和可切除胰腺癌的比较(PREOPANC-2):一项多中心随机对照试验

讲者:荷兰鹿特丹伊拉斯谟大学Bas Groot Koerkamp

摘要号:LBA77 

题目:5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): a randomized phase 3 trial sponsored by the FFCD

5-氟尿嘧啶和奥沙利铂联合或不联合多西他赛一线治疗HER2阴性的局部晚期(LA)不可切除或转移性胃或胃食管结合部(GEJ)腺癌(GASTFOX-PRODIGE 51): FFCD资助的一项随机3期试验

讲者:法国乔治·蓬皮杜欧洲医院 Aziz Zaanan

下消化道领域 

主席大会

摘要号:LBA10 

题目:Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase 3 study

Sotorasib联合panitumumab vs. 标准化疗在难治性KRAS G12C突变转移性结直肠癌(mCRC)的比较:CodeBreak 300 3期研究

讲者:意大利米兰国立癌症研究所 Filippo Pietrantonio
 
优选论文专场

摘要号:LBA27

题目:First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM):overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer Group

初始不可切除的结直肠癌肝转移(CRLM)患者的一线全身治疗:荷兰结直肠癌组III期CAIRO5研究的总生存率分析

讲者:荷兰阿姆斯特丹大学医学中心Cornelis J. Punt

摘要号:LBA28

题目:The PEGASUS trial: post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients

PEGASUS试验: III期和高危II 期结肠癌患者的术后液体活检指导治疗

讲者:意大利威尼托肿瘤研究所Sara Lonardi

摘要号:LBA29

题目:Aspirin After Standard Adjuvant Therapy for Colorectal Cancers (ASCOLT) - An International, Phase III, Randomised, Placebo-controlled Trial

阿司匹林标准辅助治疗结直肠癌(ASCOLT)——一项国际性、III期、随机、安慰剂对照试验

讲者:新加坡斐瑞医院 John W. Chia

简短口头报告专场

摘要号:LBA30

题目:Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA). First results of the randomised phase II PANIRINOX-UCGI28 study

Panitumumab (P) + FOLFIRINOX或mFOLFOX6治疗经循环DNA(cirDNA)检测的RAS/BRAF野生型(WT)肿瘤状态的不可切除转移性结直肠癌(mCRC)患者(pts):PANIRINOX-UCGI28随机2期研究的首次结果

讲者:法国蒙彼利埃癌症研究所 Thibault Mazard  

摘要号:LBA31

题目:Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: the NICHE-3 study

纳武利尤单抗联合relatlimab(抗LAG3)新辅助治疗局部晚期错配修复缺陷结肠癌:NICHE-3研究 

讲者:荷兰癌症研究所Yara L. Verschoor

摘要号:LBA32

题目:Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase 3 KEYNOTE-177 study

帕博利珠单抗与化疗治疗微卫星高度不稳定(MSI-H)/错配修复缺陷(dMMR)转移性结直肠癌(mCRC)的比较:KEYNOTE-177随机3期研究的5年随访 

讲者:英国HCA Healthcare UK Kai-Keen Shiu


(如有错误或遗漏,敬请留言指正。)


参考来源:


https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/session

责任编辑:肿瘤资讯-Bree
排版编辑:肿瘤资讯-胡一帆
               
版权声明
本文专供医学专业人士参考,未经著作人许可,不可出版发行。同时,欢迎个人转发分享,其他任何媒体、网站如需转载或引用本网版权所有内容,须获得授权,且在醒目位置处注明“转自:良医汇-肿瘤医生APP”。